Heart Failure With Normal Ejection Fraction Clinical Trial
— ILO-HOPEOfficial title:
Inhaled Iloprost and Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction - the ILO-HOPE Clinical Trial
BACKGROUND There is no effective medical treatment for heart failure with preserved ejection
fraction (HFpEF). Increases in pulmonary capillary wedge pressure (PCWP) develop in patients
with HFpEF. Prostacyclin analogo can possible reduced PA pressure along with PWCP pressure,
as with exercise.
OBJECTIVES This study try to determine whether inhlalation of iloprost improves exercise
hemodynamics and cardiac reserve in HFpEF.
METHODS In a double-blind, randomized, placebo-controlled, parallel-group trial, subjects
with HFpEF underwent invasive cardiac catheterization with simultaneous expired gas analysis
at rest and during exercise, before and 15 min after treatment with either inhaled iloprost
or matching placebo.
Status | Recruiting |
Enrollment | 34 |
Est. completion date | January 1, 2020 |
Est. primary completion date | January 1, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: 1. presence of typical HF symptoms and signs 2. LV ejection fraction = 50 3. elevated levels of NT-proBNP (at least >125 pg/ml) 4. echocardiographic structural (a left atrial volume index > 34 mL/m2 or a left ventricular mass index =115 g/m2 for males and =95 g/m2 for females) or functional alterations (E/e'=13 and a mean e' septal and lateral wall < 9 cm/s). Exclusion Criteria: 1. chronic renal failure (creatinine > 250 µmol/L) 2. significant hepatic disease, significant coronary artery disease (CAD) (coronary artery stenosis >70% without intervention or positive stress test), 3. secondary hypertension, 4. pericardial disease 5. significant valvular heart disease (>mild stenosis, >moderate regurgitation), 6. active cancer, 7. cor pulmonale 8. congenital heart disease 9. high-output heart failure 10. subjects receiving long-term treatment with phosphodiesterase 5 in-hibitors 11. chronic atrial fibrillation. |
Country | Name | City | State |
---|---|---|---|
Taiwan | National Taiwan University Hospital | Taipei |
Lead Sponsor | Collaborator |
---|---|
National Taiwan University Hospital |
Taiwan,
Borlaug BA, Koepp KE, Melenovsky V. Sodium Nitrite Improves Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2015 Oct 13;66(15):1672-82. doi: 10.1016/j.jacc.2015.07.067. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pulmonary wedge pressure changes after exercise measured by swan-ganz catheter (effect of inhalation of drug[efficacy]) | Exercise pulmonary wedge pressure changes measured by swan-ganz catheter | 15 minutes after inhalation of drugs | |
Secondary | Resing pulmonary wedge pressure measured by swan-ganz catheter (effect of inhalation of drug[efficacy]) | resting pulmonary wedge pressure changes measured by swan-ganz catheter | 15 minutes after inhalation of drugs | |
Secondary | Resting cardiac output as assessed by direct Fick method and heart rate (effect of inhalation of drug[efficacy]) | Investigators will measured cardiac output by direct Fick method and heart rate before exercise, after exercise, after inhalation of drugs(placebo/iloprost) and after second exercise. The outcomes will be the absolute value of cardiac output at rest before and after inhalation of the different drug. | 15 minutes after inhalation of drugs | |
Secondary | Resting pulmonary vascular resistance as assessed by direct Fick method and heart rate (effect of inhalation of drug[efficacy]) | Investigators will measured cardiac output and also pulmonary vascular resistance by direct Fick method and heart rate before exercise, after exercise, after inhalation of drugs(placebo/iloprost) and after second exercise. The outcomes will be the absolute value of pulmonary vascular resistance at rest before and after inhalation of the different drug. | 15 minutes after inhalation of drugs |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03549559 -
Imaging Histone Deacetylase in the Heart
|
N/A | |
Completed |
NCT02459626 -
Left Ventricular Stiffness vs. Fibrosis Quantification by T1 Mapping in Heart Failure With Preserved Ejection Fraction
|
||
Completed |
NCT02173548 -
Interleukin-1 Blockade in HF With Preserved EF
|
Phase 2 | |
Completed |
NCT03310099 -
Unsaturated Fatty Acids Enriched-diet to Improve Cardiorespiratory Fitness, Metabolic Flexibility and Glucose Tolerance in Obese Patients
|
N/A | |
Completed |
NCT02638961 -
Inspiratory Muscle Training and Functional Electrical Stimulation for Treatment of HFpEF
|
N/A | |
Completed |
NCT03871803 -
β-blockers Withdrawal in Patients With HFpEF and Chronotropic Incompetence: Effect on Functional Capacity (Preserve-HR)
|
Phase 4 | |
Completed |
NCT03672591 -
Renal Hemodynamics in Patients With HFpEF
|
||
Active, not recruiting |
NCT03624010 -
Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients
|
Phase 2 | |
Completed |
NCT03541603 -
Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF
|
Phase 2 | |
Completed |
NCT03141567 -
LYmphangiogenesis FacTors in Heart Failure States
|
||
Completed |
NCT02744339 -
Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
|
Phase 2 | |
Completed |
NCT03387813 -
Hemodynamic-GUIDEd Management of Heart Failure
|
N/A | |
Completed |
NCT03186833 -
The Heart Failure With Preserved Ejection Fraction (HFpEF) Pathophysiology Study.
|
||
Completed |
NCT03289481 -
Treatment of HFpEF With Nitrate Supplement
|
Early Phase 1 | |
Terminated |
NCT03195660 -
Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study
|
N/A | |
Completed |
NCT03226652 -
Heart Function in Patients Assessed for Sleep Apnoea
|
||
Completed |
NCT03966755 -
Unsaturated Fatty Acids to Improve Cardiorespiratory Fitness in Obesity and HFpEF
|
N/A | |
Not yet recruiting |
NCT04282850 -
Ablation Versus Medical Management of Atrial Fibrillation in HFpEF
|
N/A | |
Recruiting |
NCT03184311 -
High-intensity Interval Training in Heart Failure Patients With Preserved Ejection Fraction
|
N/A | |
Withdrawn |
NCT03317314 -
Cardiopulmonary Interactions in Patients With Heart Failure
|